NASDAQ:VERU

Veru Competitors

$10.35
-0.03 (-0.29 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.09
Now: $10.35
$10.40
50-Day Range
$10.27
MA: $13.33
$17.29
52-Week Range
$2.30
Now: $10.35
$24.57
Volume660,100 shs
Average Volume3.96 million shs
Market Capitalization$744.29 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71

Competitors

Veru (NASDAQ:VERU) Vs. MOR, ORGO, VIE, OPK, TARO, and CORT

Should you be buying VERU stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Veru, including MorphoSys (MOR), Organogenesis (ORGO), Viela Bio (VIE), OPKO Health (OPK), Taro Pharmaceutical Industries (TARO), and Corcept Therapeutics (CORT).

Veru (NASDAQ:VERU) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Veru and MorphoSys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veru00403.00
MorphoSys06402.40

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Given Veru's stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than MorphoSys.

Profitability

This table compares Veru and MorphoSys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veru-44.55%-23.72%-13.80%
MorphoSys8.76%4.51%2.25%

Risk & Volatility

Veru has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Institutional & Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 3.1% of MorphoSys shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Veru and MorphoSys' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million17.48$-18,970,000.00($0.11)-94.09
MorphoSys$80.43 million36.57$-115,380,000.00($0.91)-24.57

Veru has higher earnings, but lower revenue than MorphoSys. Veru is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Summary

MorphoSys beats Veru on 7 of the 13 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Veru and Organogenesis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veru00403.00
Organogenesis00403.00

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Organogenesis has a consensus price target of $16.50, suggesting a potential downside of 27.76%. Given Veru's higher possible upside, research analysts clearly believe Veru is more favorable than Organogenesis.

Profitability

This table compares Veru and Organogenesis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veru-44.55%-23.72%-13.80%
Organogenesis-1.61%-10.03%-2.22%

Risk & Volatility

Veru has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Institutional & Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 4.6% of Organogenesis shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 57.2% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Veru and Organogenesis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million17.48$-18,970,000.00($0.11)-94.09
Organogenesis$260.98 million11.20$-40,450,000.00($0.42)-54.38

Veru has higher earnings, but lower revenue than Organogenesis. Veru is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Veru (NASDAQ:VERU) and Viela Bio (NASDAQ:VIE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Earnings and Valuation

This table compares Veru and Viela Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million17.48$-18,970,000.00($0.11)-94.09
Viela Bio$50 million58.26$-86,430,000.00($7.02)-7.55

Veru has higher earnings, but lower revenue than Viela Bio. Veru is trading at a lower price-to-earnings ratio than Viela Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 47.0% of Viela Bio shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 31.5% of Viela Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Veru and Viela Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veru00403.00
Viela Bio05202.29

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Viela Bio has a consensus price target of $57.00, suggesting a potential upside of 7.53%. Given Veru's stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than Viela Bio.

Risk & Volatility

Veru has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Viela Bio has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Profitability

This table compares Veru and Viela Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veru-44.55%-23.72%-13.80%
Viela BioN/A-33.97%-31.49%

Summary

Veru beats Viela Bio on 8 of the 14 factors compared between the two stocks.

Veru (NASDAQ:VERU) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Veru and OPKO Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million17.48$-18,970,000.00($0.11)-94.09
OPKO Health$901.90 million3.11$-314,920,000.00($0.41)-10.20

Veru has higher earnings, but lower revenue than OPKO Health. Veru is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 28.5% of OPKO Health shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 40.9% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Veru and OPKO Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veru00403.00
OPKO Health00203.00

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. OPKO Health has a consensus price target of $9.00, suggesting a potential upside of 115.31%. Given OPKO Health's higher possible upside, analysts plainly believe OPKO Health is more favorable than Veru.

Volatility & Risk

Veru has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

Profitability

This table compares Veru and OPKO Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veru-44.55%-23.72%-13.80%
OPKO Health-9.79%-2.61%-1.80%

Summary

OPKO Health beats Veru on 9 of the 13 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Veru and Taro Pharmaceutical Industries' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million17.48$-18,970,000.00($0.11)-94.09
Taro Pharmaceutical Industries$644.77 million4.32$244.24 million$6.3511.47

Taro Pharmaceutical Industries has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Veru and Taro Pharmaceutical Industries, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veru00403.00
Taro Pharmaceutical Industries00103.00

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Taro Pharmaceutical Industries has a consensus price target of $81.00, suggesting a potential upside of 11.22%. Given Veru's higher possible upside, equities analysts plainly believe Veru is more favorable than Taro Pharmaceutical Industries.

Volatility & Risk

Veru has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Profitability

This table compares Veru and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veru-44.55%-23.72%-13.80%
Taro Pharmaceutical Industries-45.94%10.36%8.38%

Summary

Taro Pharmaceutical Industries beats Veru on 7 of the 13 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Veru and Corcept Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million17.48$-18,970,000.00($0.11)-94.09
Corcept Therapeutics$306.49 million8.68$94.18 million$0.7729.45

Corcept Therapeutics has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Veru and Corcept Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veru-44.55%-23.72%-13.80%
Corcept Therapeutics30.73%25.38%23.16%

Institutional and Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 16.4% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Veru has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Veru and Corcept Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veru00403.00
Corcept Therapeutics01102.50

Veru currently has a consensus price target of $19.25, suggesting a potential upside of 85.99%. Corcept Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Given Veru's stronger consensus rating and higher possible upside, equities analysts plainly believe Veru is more favorable than Corcept Therapeutics.

Summary

Corcept Therapeutics beats Veru on 9 of the 14 factors compared between the two stocks.


Veru Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.2%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
High Trading Volume
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71Analyst Report
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
Gap Down
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.13-1.9%$1.50 billion$7.51 million-5.22
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.